Abonnement à la biblothèque: Guest
Portail numérique Bibliothèque numérique eBooks Revues Références et comptes rendus Collections
Critical Reviews™ in Therapeutic Drug Carrier Systems
Facteur d'impact: 2.9 Facteur d'impact sur 5 ans: 3.72 SJR: 0.736 SNIP: 0.551 CiteScore™: 2.43

ISSN Imprimer: 0743-4863
ISSN En ligne: 2162-660X

Volumes:
Volume 36, 2019 Volume 35, 2018 Volume 34, 2017 Volume 33, 2016 Volume 32, 2015 Volume 31, 2014 Volume 30, 2013 Volume 29, 2012 Volume 28, 2011 Volume 27, 2010 Volume 26, 2009 Volume 25, 2008 Volume 24, 2007 Volume 23, 2006 Volume 22, 2005 Volume 21, 2004 Volume 20, 2003 Volume 19, 2002 Volume 18, 2001 Volume 17, 2000 Volume 16, 1999 Volume 15, 1998 Volume 14, 1997 Volume 13, 1996 Volume 12, 1995

Critical Reviews™ in Therapeutic Drug Carrier Systems

DOI: 10.1615/CritRevTherDrugCarrierSyst.v20.i23.30
62 pages

Emerging Trends in Oral Delivery of Peptide and Protein Drugs

Ram I. Mahato
Department of Pharmaceutical Sciences, University of Tennessee Health Science Center, 26 S. Dunlap Street, Feurt Building, Room 406, Memphis TN 38163, USA
Ajit S. Narang
Department of Pharmaceutical Sciences, University of Tennessee Health Science Center, Memphis, Tennessee, USA
Laura Thoma
Department of Pharmaceutical Sciences, University of Tennessee Health Science Center, Memphis, Tennessee, USA
Duane D. Miller
Department of Pharmaceutical Sciences, University of Tennessee Health Science Center, Memphis, Tennessee, USA

RÉSUMÉ

Most peptide and protein drugs are currently used as parenteral formulations because of their poor oral bioavailability. Development of an effective oral delivery system for these macromolecular drugs requires a thorough understanding of their physicochemical properties, such as molecular weight, hydrophobicity, ionization constants, and pH stability, as well as biological barriers that restrict protein and peptide absorption from the gastrointestinal (GI) tract, including pH variability, enzymatic degradation, and membrane efflux. Various strategies currently under investigation include amino acid backbone modifications, formulation approaches, chemical conjugation of hydrophobic or targeting ligand, and use of enzyme inhibitors, mucoadhesive polymers, and absorption enhancers. However, there is only limited success because of the hostile environment of the GI tract-e.g., strong pH extremes and abundant presence of potent luminal enzymes. Th is review focuses on the challenges posed by the GI system and how different pharmaceutical approaches can be used to make oral delivery of protein and peptide drugs more feasible. Th e roles of P-glycoprotein and CYP3A4 in controlling the extent of intestinal absorption and metabolism will also be discussed.